CenteringParenting Clinical Intervention on Kindergarten Readiness in Early Childhood
NCT03641092
Recruiting
Disparities in health begin in early childhood. Early life experiences influence brain development and have significant implications on future health and developmental outcomes. Low-income children are at greater risk of developmental delays in large part due to a lack of an enriched environment. Disparities in early childhood development increase risk for stunted academic achievement throughout the life course. Primary care is a universal exposure in early childhood and therefore is also a sign... Read More
Gender:
ALL
Ages:
3 months and below
Trial Updated:
12/20/2024
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Parent-Child Relations, Parenting, Child Development, Child Behavior
Register for Updates
Tiotropium vs. Inhaled Corticosteroids in Children With Nonatopic Asthma Pilot Study (TioNAAP)
NCT04990167
Recruiting
Most children with asthma have concurrent atopy (allergic inflammation), which is associated with an improved response to ICS. However, the absence of an atopic phenotype is associated with a poorer ICS response, leaving clinicians with limited treatment options. The nonatopic asthma phenotype has been characterized as the absence of atopic diseases including allergic rhinitis, eczema, or food allergies, and a negative skin prick test to common aeroallergens. Children with mild asthma treated wi... Read More
Gender:
ALL
Ages:
Between 6 years and 11 years
Trial Updated:
12/20/2024
Locations: Nemours Specialty Care, Jacksonville, Florida
Conditions: Asthma in Children
Register for Updates
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
NCT05605899
Recruiting
The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: University of Alabama Hospital, Birmingham, Alabama +89 locations
Conditions: High-risk Large B-cell Lymphoma (LBCL)
Register for Updates
Family Teams: A Study to Promote Team Collaboration in Family Medicine Clinics
NCT06011239
Recruiting
This project includes an intervention in five Michigan Medicine family medicine clinics which is designed to improve staff collaboration across different job roles.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: University of Michigan-Domino Farms, Ann Arbor, Michigan +4 locations
Conditions: Patient Care Team, Psychological Well-Being, Occupational Burnout
Register for Updates
A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation
NCT06218914
Recruiting
Phase I Study of NT-112, an autologous T-cell therapy product genetically engineered to express an HLA-C\*08:02-restricted T cell receptor (TCR), targeting KRAS G12D mutant solid tumors.
Gender:
ALL
Ages:
All
Trial Updated:
12/20/2024
Locations: City of Hope, Duarte, California +11 locations
Conditions: Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer, Solid Tumor, Adult, KRAS G12D
Register for Updates
VIDAS® TBI Real Life Performance in Subjects with Mild Traumatic Brain Injury (mTBI)
NCT06449183
Recruiting
Decision Rules for an initial CT-scan in patients arriving to Emergency Department (ED) and presenting a mild traumatic brain injury could be optimized by the use of an objective parameter easily and rapidly measured. This may be the place for serum biomarkers providing a quick and accurate assessment. BioMérieux has now developed an automated assay for the measurement of serum Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase (UCH-L1), the VIDAS® TBI assay to fill out th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Orlando Health, Orlando, Florida +4 locations
Conditions: Mild Traumatic Brain Injury
Register for Updates
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
NCT06663072
Recruiting
This is a phase I, open-label study to assess the safety and preliminary efficacy of Fulvestrant in combination with 177Lu-DOTATATE for advanced pNETs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Conditions: Metastatic Pancreatic Neuroendocrine Tumor
Register for Updates
The ENCIRCLE Trial
NCT04153292
Recruiting
This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Heart Center Hospital, Huntsville, Alabama +67 locations
Conditions: Mitral Regurgitation, Mitral Valve Insufficiency
Register for Updates
Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease?
NCT05094271
Recruiting
Obstructive sleep apnea (OSA) is common in older adults and has recently been implicated in pathogenesis of Alzheimer's disease (AD). Research has shown that sleep disruptions have caused memory impairment. Sleep apnea is a form of sleep disruption. We would like to examine how obstructive sleep apnea may contribute to the progression of Alzheimer's disease.
Gender:
ALL
Ages:
Between 65 years and 85 years
Trial Updated:
12/20/2024
Locations: UCSD Sleep Research, La Jolla, California
Conditions: OSA, Sleep Apnea, Obstructive Sleep Apnea, Alzheimer Disease
Register for Updates
iAmHealthy Parents First: A Televideo Parent and Child Obesity Program for Rural Families
NCT05612971
Recruiting
The purpose of this study is to assess whether providing a parent-only group program before providing a parent and child group program works better than the parent and child group program alone.
Gender:
ALL
Ages:
6 years and above
Trial Updated:
12/20/2024
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Weight Loss, Pediatric Obesity
Register for Updates
Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease
NCT06293365
Recruiting
The purpose of this study is to demonstrate the comparability of ianalumab exposure following the sub-cutaneous (s.c.) administration of one injection of 300 mg/2 mL auto-injector (AI) versus two injections of 150 mg/1 mL pre-filled syringe (PFS), and to evaluate the safety and tolerability of ianalumab following the s.c. administration of both devices in participants with rheumatoid arthritis (RA), Sjögren's disease (SjD), or systemic lupus erythematosus (SLE). A second optional cohort may be... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/20/2024
Locations: Pinnacle Research Group Llc, Anniston, Alabama +29 locations
Conditions: Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
Register for Updates
A Trial for a Preliminary Estimate of the Effectiveness of a Novel Theoretical Framework
NCT06461416
Recruiting
* Aim 1: To determine the preliminary effect sizes of al ActiveHeal EST (Engage-Sustain-Triumph) Program on occupational resilience. * Aim 2: To determine the preliminary effect sizes of ActiveHeal EST (Engage-Sustain-Triumph) on health status \[quality of life (QoL) and Psychological wellbeing (PWB)\]. * Aim 3: To determine the extent to which ActiveHeal EST (Engage-Sustain-Triumph) Program is an acceptable and feasible Intervention for breast and prostate cancer survivors.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/20/2024
Locations: University of Arkansas for Medical Science, Fayetteville, Arkansas
Conditions: Prostate Cancer, Breast Cancer
Register for Updates